BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will enter into an accelerated share repurchase (“ASR”) program to repurchase $25 million of its outstanding common stock.
“Anika’s strong balance sheet and cash flow enable us to return value to shareholders through share repurchases, while continuing to invest in our business to drive long-term growth,” said Dr. Charles H. Sherwood, President and Chief Executive Officer. “This program reflects our confidence in the business and deep commitment to creating shareholder value in both the near- and long-term.”
